Pfizer(PFE)

Material Event filed 2026-05-05

Quarterly Report filed 2026-05-05

What is Non-Muscle Invasive Bladder Cancer? mokad01 Mon, 05/04/2026 - 09:46 What is Non-Muscle Invasive Bladder Cancer? Monday, May 04, 2026 - 10:30am Share According to recent research, bladder cancer is the 12 th most common type of cancer worldwide. 1 Of these cases, doctors stage (referring to the process of how far the cancer has progressed) about 75% as non-muscle invasive bladder cancer (NMIBC). 1 Unlike other forms of bladder cancer, NMIBC only develops in cells that line the inside of the bladder, also known as urothelial or transitional cells. 2   The bladder is made up of several layers, and in most cases, bladder cancer begins in the innermost layer. With NMIBC, cancer typically remains confined to the lining of the bladder and may extend into the connective tissue without reaching the muscle layer. Because of this, doctors classify NMIBC as an early-stage cancer, usually stage 1. 3   Understanding where cancer develops within the bladder is essential, as it helps

April Social Media Round-Up—Trailblazer Cancer Research Grants, World Health Day, and More kimkevin Fri, 05/01/2026 - 14:13 April Social Media Round-Up—Trailblazer Cancer Research Grants, World Health Day, and More Friday, May 01, 2026 - 03:30pm Share April has come to a close and we are barreling towards the summer. Before you head outside to enjoy spring, take a moment to catch up with Pfizer’s social channels, which have been on fire. In April, Pfizer colleagues were honored in the list of 2026 Healthcare Businesswomen’s Association (HBA) Luminaries and Rising Stars, we recognized vaccines’ impact during World Immunization Week, and Pfizer scientists highlighted our research efforts. CEO Albert Bourla recognized Pfizer scientists who were awarded research grants by the American Association for Cancer Research, while our executive leadership announced a new partnership for the Every Breakthrough Matters campaign, shared updates in cancer research, and more. Check out updates across o

Making Progress Against Cancer - From Cancer Research to Prevention and Screening kimkevin Wed, 04/29/2026 - 15:18 Making Progress Against Cancer - From Cancer Research to Prevention and Screening Thursday, April 30, 2026 - 10:00am Share Advances in cancer care often begin with incremental steps in the lab that, over time, have the power to drive transformative breakthroughs. That’s why scientists are working around the clock to develop potential treatments that could help patients live longer, healthier lives. At Pfizer, Sharsti Sandall is one of those scientists. An executive director in Pfizer’s oncology research division, Sandall leads the antibody drug conjugate (ADC) group, which is a targeted treatment that delivers cancer-killing drugs directly to tumors. “People often think of them as really smart drugs,” says Sandall in a recent Pfizer video. Sandall went on to share that she and her colleagues think about patients in everything they do, whether they’re reading scientific pap

Final Report: A Phase 3, Randomized, Placebo- Controlled, Observer-Blinded Trial to Evaluate the Safety of a 6-Valent OspA-Based Lyme Disease Vaccine (LB6V) in Healthy Children 5 Through 17 Years of Age chavak11 Tue, 04/28/2026 - 09:09 PF-07307405 PF-07307405 PHASE III Mon, 12/12/2022 - 12:00 Mon, 07/21/2025 - 12:00 NCT05634811 C4601012 Public Disclosure Synopsis .pdf (104.22 KB) N https://clinicaltrials.gov/study/NCT05634811?term=%20C4601012&viewType=Card&rank=1 C4601012

Material Event filed 2026-04-27

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Ponsegromab in Patients With Cancer, Cachexia, and Elevated Concentrations of GDF-15, Followed by An Optional Open-Label Treatment Period chavak11 Wed, 04/22/2026 - 08:00 Ponsegromab (PF-06946860) Ponsegromab (PF-06946860) PHASE II Mon, 11/21/2022 - 12:00 Wed, 04/23/2025 - 12:00 NCT05546476 C3651003 Public Disclosure Synopsis.pdf (111.55 KB) N https://clinicaltrials.gov/study/NCT05546476?term=C3651003&viewType=Card&rank=1 C3651003

An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors soansm01 Wed, 04/22/2026 - 05:02 Marstacimab (PF-06741086) Marstacimab (PF-06741086) PHASE III Mon, 03/09/2020 - 12:00 Tue, 04/29/2025 - 12:00 NCT03938792 B7841005 Final Public Disclosure Synopsis .pdf (126.25 KB) N https://clinicaltrials.gov/study/NCT05145127?term=B7841005&viewType=Card&rank=1 B7841005

Final Report - A Phase 2b, Randomized, Observer- Blinded Trial to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on 2 Different Dosing Schedules in Healthy Participants ≥11 to <15 Years of Age chavak11 Tue, 04/14/2026 - 07:02 Neisseria meningitidis Groups A, B, C, W, and Y Vaccine (MenABCWY) PF-06886992 PHASE II Wed, 06/17/2020 - 12:00 Fri, 01/05/2024 - 12:00 NCT04440176 C3511004 Public Disclosure Synopsis .pdf (263.23 KB) N https://clinicaltrials.gov/study/NCT04440176?term=C3511004&viewType=Card&rank=1 C3511004

How Biomarker Testing Helped a Lung Cancer Patient Get the Treatment She Needed kimkevin Mon, 04/13/2026 - 16:47 How Biomarker Testing Helped a Lung Cancer Patient Get the Treatment She Needed Wednesday, April 15, 2026 - 09:00am Share Earlier this month, Science Will Win, Pfizer’s award-winning podcast, wrapped up another successful season. Launched in February, season 6 included five episodes, each one focused on a different aspect of the fight against cancer, wrapping with last week’s season finale about AI’s impact on cancer care. All season long, each podcast episode has been accompanied by a full-length video conversation between host Dr. Raven Baxter – a molecular biologist and science educator – and one of her guests, giving you more of the story, more context, and more opportunities to connect beyond the audio episode. You can watch these interviews on Pfizer’s YouTube channel here . In the second episode of the season, which explored biomarkers and precision medicine’s role in